Genmab A/S Stock Other OTC
Stocks
GNMSF
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 99.4B 15.4B 13.3B 12.26B 11.47B 21.5B 1,464B 21.84B 145B 56.44B 713B 57.81B 56.57B 2,467B | P/E Ratio 2026 * |
21.4x | P/E Ratio 2027 * | 14.9x |
|---|---|---|---|---|---|
| Enterprise Value | 119B 18.42B 15.91B 14.66B 13.73B 25.72B 1,751B 26.12B 173B 67.5B 852B 69.14B 67.67B 2,951B | EV / Sales 2026 * |
4.3x | EV / Sales 2027 * | 3.45x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | -1.32% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.32% | +1.72% | - | - | 15.3B | |
| +1.03% | +2.30% | +54.92% | +111.78% | 55.58B | |
| +2.72% | +3.06% | +53.28% | +47.85% | 43.47B | |
| +1.12% | +2.79% | -13.71% | -17.53% | 22.64B | |
| +1.17% | +3.85% | +1.00% | +401.79% | 20.96B | |
| +3.81% | -4.13% | +16.62% | -30.70% | 15.79B | |
| -0.69% | +0.82% | +27.17% | +178.31% | 13.45B | |
| +5.27% | +6.41% | +21.05% | - | 11.74B | |
| +1.61% | +1.17% | +90.79% | +212.97% | 10.96B | |
| +1.37% | -1.28% | +61.76% | +80.92% | 10.93B | |
| Average | +1.61% | +0.32% | +34.77% | +123.17% | 22.84B | |
| Weighted average by Cap. | +1.59% | +1.28% | +37.10% | +110.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.65B 4.28B 3.7B 3.41B 3.19B 5.98B 407B 6.07B 40.26B 15.7B 198B 16.08B 15.74B 686B | 32.41B 5.02B 4.34B 4B 3.74B 7.01B 477B 7.12B 47.2B 18.4B 232B 18.85B 18.45B 805B |
| Net income | 4.71B 730M 631M 581M 544M 1.02B 69.4B 1.04B 6.86B 2.68B 33.78B 2.74B 2.68B 117B | 7.02B 1.09B 939M 866M 810M 1.52B 103B 1.54B 10.22B 3.99B 50.32B 4.08B 4B 174B |
| Net Debt | 19.49B 3.02B 2.61B 2.4B 2.25B 4.22B 287B 4.28B 28.39B 11.07B 140B 11.34B 11.1B 484B | 12.47B 1.93B 1.67B 1.54B 1.44B 2.7B 184B 2.74B 18.16B 7.08B 89.42B 7.25B 7.1B 310B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
